Staidson (Beijing) Biopharmaceuticals Co., Ltd. engages in the research and development, production, and marketing of innovative drugs with independent intellectual property rights. It focuses on the development, production, and sale of safe and effective therapeutic drugs, which are subdivided into three directions: protein drugs, gene drugs and chemical drugs. Its therapeutic areas cover nerve-damaged diseases, infectious diseases, gastrointestinal diseases, urinary system diseases, and autoimmune diseases. The company was founded on August 16, 2002 and is headquartered in Beijing, China.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company